8 completed, 3 terminated, 1 recruiting. 12 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 8, Terminated 3, Recruiting 1 |
| Phase 1 | 2 | Completed 2 |
Follow Biotest: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Cytotect®CP, Hyperimmune Anti-CMV IVIg as CMV Prophylaxis in Patients Developing Acute Grade II-IV GVHD After Allogeneic Hematopoietic Cell Transplantation. Cytotect®CP - Cytomegalovirus Infections | Phase 2 | Terminated | University Hospital, Lille | 2 | 2022-09-13 | 2025-09-30 |
| Treatment of Patients With Chronic Hepatitis B With Hepatitis B Immunoglobulins Human hepatitis B Immunoglobulin (Hepatect®CP/Zutectra®) - Chronic Hepatitis B | Phase 2 | Terminated | Hannover Medical School | 13 | 2022-08-15 | 2025-09-04 |
| Association of T Gamma Delta-CD16+ Cells and Anti-CMV Immunoglobulins in the Prevention of CMV Infection Cytotect - Kidney Transplantation, CMV Infection | Phase 2 | Completed | University Hospital, Bordeaux | 42 | 2021-11-17 | 2026-05-12 |
| Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19 Trimodulin, Placebo (human albumin 1%) - Covid19 | Phase 2 | Completed | Biotest | 166 | 2020-10-06 | 2023-01-10 |
| Prospective, Randomized Trial of Personalized Medicine With Pentaglobin® After Surgical Infectious Source Control in Patients With Peritonitis Pentaglobin®/Standard of Care - Peritonitis, Sepsis | Phase 2 | Recruiting | RWTH Aachen University | 200 | 2017-11-20 | 2026-06-11 |
| Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus BT063, Placebo - Systemic Lupus Erythematosus | Phase 2 | Completed | Biotest | 36 | 2015-09-28 | 2020-01-27 |
| Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis Tregalizumab, Placebo - Rheumatoid Arthritis | Phase 2 | Terminated | Biotest | 321 | 2013-10-01 | 2017-08-24 |
| BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma BT062 , intravenous administration - Multiple Myeloma | Phase 1 / Phase 2 | Completed | Biotest Pharmaceuticals Corporation | 64 | 2012-07-03 | 2019-07-23 |
| Safety and Efficacy Study of BT086 to Evaluate Adjunctive Therapy in sCAP BT086, 1% Human Albumin infusion - Community Acquired Pneumonia | Phase 2 | Completed | Biotest | 160 | 2011-08-01 | 2015-07-29 |
| Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX) BT061, Placebo - Rheumatoid Arthritis | Phase 2 | Completed | Biotest | 127 | 2010-12-01 | 2015-02-20 |
| Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma BT062 - Multiple Myeloma | Phase 1 / Phase 2 | Completed | Biotest Pharmaceuticals Corporation | 35 | 2010-08-01 | 2019-07-30 |
| Safety and Efficacy of Multiple Doses of BT061 in Patients With Moderate to Severe Chronic Plaque Psoriasis BT061, placebo treatment - Psoriasis Vulgaris | Phase 2 | Completed | Biotest | 49 | 2010-02-01 | 2012-03-13 |
Arthritis, Rheumatoid (2) · Community-Acquired Pneumonia (2) · Cytomegalovirus Infections (2) · Multiple Myeloma (2) · Autoimmune Diseases (1) · COVID-19 (1) · Hepatitis B, Chronic (1) · Lupus Erythematosus, Systemic (1) · Peritonitis (1) · Pneumonia, Bacterial (1) · Recurrence (1) · Respiratory Distress Syndrome (1) · Sepsis (1) · Shock, Septic (1)
indatuximab ravtansine (2) · Administration, Intravenous (1) · cytomegalovirus-specific hyperimmune globulin (1) · hepatitis B hyperimmune globulin (1) · tregalizumab (1) · trimodulin (1)
Germany (5) · Czechia (3) · France (3) · Hungary (3) · Poland (3) · Spain (3) · United States (3) · Russia (2) · Serbia (2) · Austria (1) · Belarus (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · Canada (1)
Antoni Torres, MD (1) · Gernot Marx, Univ.-Prof. (1) · Heiner Wedemeyer, Prof. (1) · Ibrahim Yakoub-Agha, MD,PhD (1) · Kenneth C Anderson, MD (1) · Kenneth C. Anderson, MD (1) · Nemanja Damjanov, Professor (1) · Ronald van Vollenhoven, Prof. MD (1) · Tobias Welte, MD (1)
PMID 29343509, PMID 29632995, PMID 30832742, PMID 33351126, PMID 33687069, PMID 34529955, PMID 39138518
2016 (1)